Aegis Capital Initiates Recro Pharma (REPH) at Buy, $40 PT; Sees as 'Risk-Mitigated', 'Undervalued'
Tweet Send to a Friend
Aegis Capital starts Recro Pharma (Nasdaq: REPH) at Buy and 18-month price target of $40, suggesting massive upside from a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
